A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of NOVA63035 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy.

Trial Profile

A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of NOVA63035 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Nova 63035 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Most Recent Events

    • 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 15 Jul 2010 Planned end date changed from 1 Oct 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 07 Oct 2009 Planned number of patients changed from 23 to 24 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top